Reports
| Status | Drug name | NICE TAs | Comments | |
|---|---|---|---|---|
|
Leniolisib (Joenja ®) | |||
|
|
Lenvatinib (Kisplyx®) | |||
|
Letrozole tablets | |||
|
Linzagolix (Yselty®) | |||
|
|
Liraglutide (Saxenda®) (GLP1s should all be prescribed by brand name) |
The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Saxenda®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. |
||
|
Liraglutide (Victoza®) injection (GLP1s should all be prescribed by brand name) |
THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity. 1.8 mg is non-formulary. |
||
|
|
Lisocabtagene maraleucel (liso‑cel) (Breyanzi®) |
|
||
|
|
Lorlatinib (Lorviqua®) | |||
|
|
Lumacaftor-ivacaftor (Orkambi®) | |||
|
|
Lusutrombopag (Mulpleo®) |
